Photobiomodulation Research (LLLT)

There are over 5,000 studies on Photobiomodulation, previously LED Light Therapy (LLLT - Low Level Light Therapy), now called Photobiomodulation therapy or PBMt.   We recommend the NIH website for controlled, peer reviewed and published studies to get what may be the best pure science.  Manufacturer based studies are frequently skewed to the biases of the manufacturer and the products they sell.

The ARRC LED consults with Dr. Michael Hamblin of Harvard / MIT arguably the world’s leading expert on full body PBMt. In addition we consult with industry leaders including Dr. Michael Ko of Osram Optoelectronics (phd in chemistry from Johns Hopkins) and we work with the engineering staff of two publically traded companies in the development of our systems. Driven by innovation our systems are entrenched in scientific theory.

Below are photobiomodulation research studies found on the NIH website linked to specific conditions.
When you click the links below you will be taken to supporting research for that condition on the National Institute of Health website.  The right hand sidebar on the NIH website shares similar studies for that condition.   To go deeper into research on a specific condition you can either click onto similar studies or perform a search on the NIH site search bar at the top of the page.  These are medical studies with terminology that can be difficult for most.   If you are not familiar with medical terms, you might choose to read the Conclusion at the bottom of each page first.



Read what researchers from Mass General, Harvard and Boston University conclude about LED Light Therapy. We are delighted to have Dr Hamblin consult with us on the development of new PBMt projects and look forward to helping this man share the wisdom through an upcoming series of short, condition specific podcasts.

There have been a large number of both animal model and clinical studies that demonstrated highly beneficial LLLT effects on a variety of diseases, injuries, and has been widely used in both chronic and acute conditions (see Figure 7). LLLT may enhance neovascularisation, promote angiogenesis and increase collagen synthesis to promote healing of acute (Hopkins et al. 2004) and chronic wounds (Yu et al. 1997). LLLT provided acceleration of cutaneous wound healing in rats with a biphasic dose response favoring lower doses (Corazza et al. 2007). LLLT can also stimulate healing of deeper structures such as nerves (Gigo-Benato et al.2004), tendons (Fillipin et al. 2005), cartilage (Morrone et al. 2000), bones (Weberet al. 2006) and even internal organs (Shao et al. 2005). LLLT can reduce pain (Bjordal et al. 2006a), inflammation (Bjordal et al. 2006b) and swelling (Carati et al. 2003) caused by injuries, degenerative diseases or autoimmune diseases. Oron reported beneficial effect of LLLT on repair processes after injury or ischemia in skeletal and heart muscles in multiple animal models in vivo (Ad and Oron 2001;  Oron et al. 2001a;   Oron et al. 2001b;  Yaakobi et al. 2001). LLLT has been used to mitigate damage after strokes (in both animals (Lapchak et al. 2008) and humans (Lampl et al. 2007)), after traumatic brain injury (Oron et al. 2007) and after spinal cord injury (Wu et al. 2009).

Beneficial tissue effects of LLLT can include almost all the tissues and organs of the body. 2.8. Downstream cellular response